Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203811 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Study to Evaluate HTI-2088 Tablet
A Phase 1 study of Diabetes, sponsored by Hengrui Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03203811 is a Phase 1 study of Diabetes that has completed, run by Hengrui Therapeutics. The registered enrollment target is 40 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03203811, a Phase 1 study of Diabetes, has completed, sponsored by Hengrui Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Single Center, Randomized, Double Blind, Placebo Controlled, Single ascending dose trial at 3 levels. Ten subjects will be enrolled at each dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HTI-2088
Study Locations (1)
Ohio
- Medpace - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-02-17 |
| Est. Completion | 2017-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03203811
The ClinicalTrials.gov registry entry for NCT03203811 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Hengrui Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03203811 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03203811 about?
NCT03203811 is a clinical study titled "A Phase 1, Study to Evaluate HTI-2088 Tablet". Single Center, Randomized, Double Blind, Placebo Controlled, Single ascending dose trial at 3 levels. Ten subjects will be enrolled at each dose.
What is the current status of trial NCT03203811?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-02-17. Estimated completion is 2017-10-23.
What conditions does trial NCT03203811 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT03203811?
The interventions under investigation include: Placebo (DRUG), HTI-2088 (DRUG).
Who is sponsoring clinical trial NCT03203811?
This trial is sponsored by Hengrui Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03203811 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
RECRUITING · Phase 1
-
Insulin Balanced Infusion System
ACTIVE NOT RECRUITING · Phase 1
-
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
COMPLETED · Phase 1
-
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
COMPLETED · Phase 1
-
Family Management of Childhood Diabetes Study
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.